Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02354443 · ClinicalTrials.gov registry record · Phase 1
A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders
A Phase 1 study, sponsored by Fate Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT02354443 is a Phase 1 study that was terminated before completion, run by Fate Therapeutics. The registered enrollment target is 1 participants.
The verdict
NCT02354443, a Phase 1 study, was terminated before completion, sponsored by Fate Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to describe the safety profile of ProHema-CB as part of a single cord blood unit transplant after a myeloablative conditioning regimen in pediatric patients with inherited metabolic disorders. The safety profile will primarily be assessed by neutrophil engraftment.
Interventions
- BIOLOGICAL ProHema-CB Transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2015-06 |
| Est. Completion | 2017-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02354443
The ClinicalTrials.gov registry entry for NCT02354443 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fate Therapeutics, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ProHema-CB Transplant is the first listed.
NCT02354443 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02354443 about?
NCT02354443 is a clinical study titled "A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders". The purpose of this study is to describe the safety profile of ProHema-CB as part of a single cord blood unit transplant after a myeloablative conditioning regimen in pediatric patients with inherited metabolic disorders. The safety profile will primarily be assessed by neutrophil engraftment.
What is the current status of trial NCT02354443?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2015-06. Estimated completion is 2017-02.
What interventions are being tested in trial NCT02354443?
The interventions under investigation include: ProHema-CB Transplant (BIOLOGICAL).
Who is sponsoring clinical trial NCT02354443?
This trial is sponsored by Fate Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.